secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0000950170-23-000458
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron reports preliminary FY2022 revenue $106.7M (+24% YoY); oncology franchise beats guidance
--------------------------------------------------------------------------------

- Preliminary full-year 2022 net product sales $106.7M, up 24% YoY; oncology franchise $96.6M vs guidance $93-95M.
- Q4 2022 ZYNRELEF net sales ~$3.8M, up 40% vs Q3; demand units 20,765 (+38%).
- Full-year 2023 oncology franchise guidance $99-103M; APONVIE launch expected Q1 2023.
- sNDA for expanded ZYNRELEF indication submitted to FDA Dec 2022; 10-month action date.
- NOPAIN Act provides separate CMS reimbursement for ZYNRELEF through Dec 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017023000458/0000950170-23-000458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017023000458/hrtx-20230109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer